描述 |
Dutasteride (GG745)是5α还原酶同工酶抑制剂,还可能因其结构域DHT相似对雄激素受体(AR)产生脱靶效应。 |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
相关类别 |
|
||||||||||||
溶解度 |
体外:
DMSO:33.33 mg / mL(63.06 mM;需要超声波) 体内:1。逐个添加每种溶剂:10%DMSO 90%玉米油溶解度:≥2.5mg / mL(4.73 mM);明确解决方案
|
||||||||||||
储备液 |
|
||||||||||||
存储 |
|
||||||||||||
运输 |
室温;可能会有所不同 |
||||||||||||
SMILES |
O=C([C@H]1CC[C@]2([H])[C@]1(C)CC[C@]3([H])[C@@]4(C)C=CC(N[C@]4([H])CC[C@]32[H])=O)NC5=CC(C(F)(F)F)=CC=C5C(F)(F)F |
||||||||||||
参考文献 |
|
||||||||||||
相关活性 小分子 |
非那雄胺 | 爱普列特 | CGP-53153 |
密度 | 1.3±0.1 g/cm3 |
---|---|
沸点 | 620.3±55.0 °C at 760 mmHg |
熔点 | 242-250?C |
分子式 | C27H30F6N2O2 |
分子量 | 528.530 |
闪点 | 329.0±31.5 °C |
精确质量 | 528.221130 |
PSA | 58.20000 |
LogP | 5.61 |
外观性状 | 白色结晶固体 |
蒸汽压 | 0.0±1.8 mmHg at 25°C |
折射率 | 1.523 |
储存条件 | -20°C Freezer |
水溶解性 | DMSO: soluble2mg/mL, clear |
危险品运输编码 | NONH for all modes of transport |
---|---|
海关编码 | 2942000000 |
海关编码 | 2933990090 |
---|---|
中文概述 | 2933990090. 其他仅含氮杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0% |
申报要素 | 品名, 成分含量, 用途, 乌洛托品请注明外观, 6-己内酰胺请注明外观, 签约日期 |
Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro J. Steroid Biochem. Mol. Biol. 144 Pt B , 436-44, (2014)
? Dutasteride and abiraterone were evaluated for inhibition of steroidogenesis. ? Bypass mechanisms arise in the presence of abiraterone to form DHT. ? Dutasteride inhibits T and DHT effectively in vi…
|
|
Preparation of microcapsules with the evaluation of physicochemical properties and molecular interaction. Arch. Pharm. Res. 37(12) , 1570-7, (2014)
The objective of this study was to prepare and characterize dutasteride (a hydrophobic model drug) microcapsules using ethyl cellulose as a capsule shell polymer with different drug/polymer ratios of …
|
|
Long term effectiveness on prescribing of two multifaceted educational interventions: results of two large scale randomized cluster trials. PLoS ONE 9(10) , e109915, (2014)
Information on benefits and risks of drugs is a key element affecting doctors’ prescribing decisions. Outreach visits promoting independent information have proved moderately effective in changing pre…
|
|
(5a,17b)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide |
(5α,17β)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide |
Avodart |
Duagen |
α,α,α,α’,α’,α’-Hexafluoro-3-oxo-4-aza-5α-androst-1-ene-17β-carboxy-2′,5′-xylidide |
Dutasteride |
(4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-[2,5-Bis(trifluoromethyl)phenyl]-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide |
1H-Indeno[5,4-f]quinoline-7-carboxamide, N-[2,5-bis(trifluoromethyl)phenyl]-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- |
a,a,a,a’,a’,a’-Hexafluoro-3-oxo-4-aza-5a-androst-1-ene-17b-carboxy-2′,5′-xylidide |